Early case detection is crucial for ending tuberculosis (TB). Though the TB diagnostic pipeline has advanced significantly in recent years, significant challenges remain for the rapid and accurate detection of TB and drug-resistant TB.
In 2014, in an effort to inform and help steer research and development (R&D) priorities for TB diagnostic tools, the World Health Organization released its high-priority target product profiles for new TB diagnostics, including target product profiles for next-generation drug-susceptibility testing(DST) at microscopy centres. As the set timeframe for these targets has expired, WHO, along with the New Diagnostics Working Group, have embarked in their revision.
As part of the revision process, WHO is initiating a public comment process for partners and stakeholders to provide inputs on the updated high-priority target product profiles for next-generation DST. All comments submitted through this process will be carefully considered in the development of the draft 1.0 of these target product profiles, before it is submitted for final revision through a Stakeholder Consultation planned for February 2021.
To submit your comments please use the online survey tool to access the draft document.
Any questions or additional comments pertaining to this process can be addressed to gtbprogramme@who.int.
You can submit your comments through this platform from 7 – 31 January 2021, 18:00 CET.
